Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIOs on-demand session, Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.

Among the many challenges is the fact that Alzheimers disease and many other neurodegenerative diseases develop slowly.

By the time symptoms manifest, the disease has evolved and become complicated, panel moderator Selina Koch, executive editor for BioCentury, Inc. noted.

Therefore, the panelists are wrestling with how to identify and treat patients early and whether to look at individual pathways or develop a polypharmacologic approach involving multiple pathways.

We believe that, as with cancer, you have to hit several areas with, maybe, a combination of therapies, Elizabeth Jeffords, chief commercial and & strategy officer at Alkahest, said. Our approach is to look at the plasma proteome to understand which proteins change with age and, among them, which are important biological drivers not just reporters for neurodegenerative diseases.

One of the challenges in developing neurodegenerative drugs is the inability to target specific cell types in the brain, but, more importantly, its important to understand not just germ line mutations but what makes them vulnerable to mutations, Brad Margus, CEO of Cerevance said.

By sorting nuclei from various types of cells taken from post-mortem human tissue from brain banks, Cerevance gains a broader perspective than is possible by single cell analysis.

We feel were getting to the real problem, seeing changes in genes (that wouldnt be evident with single cell analysis.) This may help identify novel target beyond amyloid and tau, he said.

Esya Labs, a seed-stage company, is focused on Alzheimers disease and lysosomal disorders with the goal of developing tools to match patients to therapies.

We have three different approaches: one identifies which lysosomal storage drugs work on patients, the second identifies patterns in the manifestation of those diseases, and the third will make a diagnostic, Dhivya Venkat, CEO and co-founder, told listeners.

Her company has identified signatures for Alzheimers and how it manifests across the lysosome, suggesting there may be many sub-type of the disease. Therefore, since 60% of the factors that determine whether individuals respond to a drug is genetic, we need to identify which patients respond best to particular targets, and to develop ways to validate those targets early on.

Ideally, patients would be diagnosed very early in the onset of the disease, before symptoms appear. Eysa Labs has found traces of neurodegenerative disease in the circulating cells that may help with that. By looking at the signatures of the macrophages, you can profile the endosome, golgi and lysosome and have an indication of whats happening in the brain. If functional structures are degrading, protein builds up, Venkat explained.

Cell types react differently to aging, Margus added. Cerevance researchers have studied brain tissues from donors aged 8 to 97 and overlaid some of those changes onto disease models. At a high level, the brain of a typical Parkinsons patient at age 60 has the signature of healthy person of 70 or 75.

Applying that to preclinical research may be challenging. Its hard to find aged mice, Jeffords quipped. Instead, much of the preclinical work is performed on African green monkeys.

Virscio, a preclinical contract research organization specializing in non-human primates, has a facility for such research in the Caribbean. It focuses on de-risking drugs. From that facility, Matthew Lawrence, CEO and SCO of Virscio, said his organization is looking at the inducible form of Alzheimers in young and old animals to enable the design of screening studies that will align as closely as possible to humans. Gender differences play a role, too, he added.

Many neurodegenerative disorders, aside from Parkinsons, are womens diseases, Jeffords pointed out. Going forward, two-thirds or more of the Alzheimers cohort will be women, but clinical studies today dont take that into account. Only 20 25% of all clinical studies for all diseases include women.

Those figures hold true for in vitro cell studies, too.

The rationale, Lawrence explained, was that we historically enrolled men or women based on the stereotaxic coordinates for which we had the biometry already determined for that given sex, as well as concerns about hormonal cycles affecting the data. Over the past decade, science has appreciated that the hormonal variable has meaningful biological ramifications for the interpretation of translational utility of that data. As industry demands gender balance, it will be further emphasized.

The results of including female cells in preclinical work and females as clinical trial participants could have a significant effect on outcomes. Jeffords cited one study in which, she said, The 17% of trials that segregated results by gender saw a difference between the sexes in the response to the agents they were testing. Its worth a look.

As neurodegenerative research advances, the panelists expect it to adopt many of the lessons learned from the COVID-19 pandemic. The most notable may be the widespread realization of the importance of preventing diseases and of diagnosing diseases earlier so they can be better managed.

That suggests the need for the continued advance of personalized medicine. That, in turn, requires a deeper understanding of individual diseases, their mechanisms of action, and the role of genetics in their onset. The biomarkers being hinted at today will likely play a huge role in addressing neurodegenerative diseases and therapies in the relatively near future.

More:
BIO 2020: Neurodegenerative Therapies Need a Personalized Approach - BioSpace

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "Global Leukemia Therapeutics Market By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Genetics, Others), By Severity, By Blood Cell, By Age Groups, By Sex, By Treatment, By Diagnosis, By Route of Administration, By Drugs, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Leukemia Therapeutics Market is expected to grow at a formidable rate during the forecast period.

The market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Furthermore, supportive government initiatives & policies for promoting cancer awareness is anticipated to fuel the market growth until 2025.

The market can be segmented based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and region. Based on severity, the market can be bifurcated into acute and chronic. The chronic leukemia segment is expected to dominate the market during forecast period. This can be accredited to the rising geriatric population and increasing funding for cancer research and the development of new therapies.

Regionally, the Global Leukemia Therapeutics Market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market during forecast period. This can be attributed to the presence of a large geriatric population base in the country. Additionally, the presence of key players in the region is further expected to propel the market over 2025.

Major players operating in the Global Leukemia Therapeutics Market include Novartis, AbbVie, Bristol-Myers Squibb, Roche, Amgen, Gilead sciences, Celgene, Eisai, AstraZeneca, Incyte Corporation, Johnson & Johnson, Biogen, Merck, PerkinElmer, Eli Lilly, Abbott, Sumitomo Dainippon Pharma, Thermo Fisher Scientific, Otsuka Holdings, Astellas Pharma and others. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in August 2017, Bristol-Myers Squibb acquired IFM Therapeutics in order to fortify its oncology product line.

Years considered for this report:

Objective of the Study

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Leukemia Therapeutics Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value & Volume

5.2. Market Share & Forecast

5.2.1. By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Genetics, Immune suppression, Others)

5.2.2. By Severity (Acute, Chronic)

5.2.3. By Blood Cell (Lymphocytic, Myelogenous)

5.2.4. By Age Groups (0-15, 15-30, 30-50, 50+)

5.2.5. By Sex (Male, Female)

5.2.6. By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Immunotherapy, Vaccine Therapy, Chemotherapy, Blood Transfusion)

5.2.7. By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining (CT-SCAN, X-RAY, MRI))

5.2.8. By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal)

5.2.9. By Drugs (Antimetabolites, Biosimilars, Asparagine-Specific Enzymes, Hormones (Corticosteroids), Hypomethylating (Demethylating) Agents, Tyrosine Kinase Inhibitors, Others)

5.2.10. By Company (2019)

5.2.11. By Region

5.3. Market Attractiveness Index

6. Asia-Pacific Leukemia Therapeutics Market Outlook

7. Europe Leukemia Therapeutics Market Outlook

8. North America Leukemia Therapeutics Market Outlook

9. South America Leukemia Therapeutics Market Outlook

10. Middle East and Africa Leukemia Therapeutics Market Outlook

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

13.1. Competition Outlook

13.2. Players Profiled (Leading Companies)

13.2.1. Novartis

13.2.2. AbbVie

13.2.3. Bristol-Myers Squibb

13.2.4. Roche

13.2.5. Amgen

13.2.6. Gilead Sciences

13.2.7. Celgene

13.2.8. Eisai

13.2.9. AstraZeneca

13.2.10. Incyte Corporation

13.2.11. Johnson & Johnson

13.2.12. Biogen

13.2.13. Merck

13.2.14. PerkinElmer

13.2.15. Eli Lilly

13.2.16. Abbott

13.2.17. Sumitomo Dainippon Pharma

13.2.18. Thermo Fisher Scientific

13.2.19. Otsuka Holdings

13.2.20. Astellas Pharma

14. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/2sotj2

See the original post:
Global Leukemia Therapeutics Market Forecast and Opportunities to 2025 - ResearchAndMarkets.com - Business Wire

Recommendation and review posted by Bethany Smith

KINGSTON, R.I. June 9, 2020 Men are taller than women because millennia ago big, strong men beat out their shorter rivals for access to mates. The female pelvis is broader than the male pelvis because women have evolved to give birth. So the thinking goes.

Theyre compelling evolutionary narratives that have lasted in textbooks, classrooms and pop culture as explanations for the skeletal differences between men and women. But as explanations, these simple stories no longer stand up to current science, says Holly Dunsworth, associate professor of anthropology at the University of Rhode Island.

Poring over decades of existing research, Dunsworth has reevaluated and rewritten the narrow, reigning theories for sex difference in height and pelvic width in a new paper, Expanding the evolutionary explanations for sex differences in the human skeleton. The paper, published online by the journal Evolutionary Anthropology, maps out the critical role of estrogen production on bone growth in men and women.

A lot of these conventions and how they support these old stories, such as sexual selection made men taller, are out of a tradition where we really only had skeletons to study, says Dunsworth. People hadnt done behavioral observations, or studied the physiology or the genetics. There have been so many advances in 150 years of human biology, and when you put all these things together, the old origin stories dont add up.

In rewriting the explanations, Dunsworth waded through hundreds of existing studies. Her paper cites 94 references, but she reviewed five times that. I tried not to go too far back. The further I went the more misconceptions I found, she says. I think there is an old assumption out there that testosterone makes men taller, but thats just not the science.

In her paper, Dunsworth focuses on how different levels of estrogen production dictate bone growth in both sexes, with ovaries producing more estrogen than testes. Boys and girls grow at roughly the same pace, reaching about 62 inches by age 13. At that age, greater estrogen production in girls causes long bone growth plates to fuse. Boys continue to grow taller for about five more years, until they reach levels of estrogen that fuse their bones. In that time, boys grow another 8 inches on average; girls just 2. As with height, sex differences in the pelvis skeleton are also rooted in the differing levels of estrogen and its effects over time on differing systems of gonads, genitals, ligaments and bones.

There are ways that men and women are so obviously different in their evolved reproductive physiology, Dunsworth says. Its really as if the reigning theories just look at the skeleton to claim that men are taller because they evolved to be dominant and competitive as if women didnt and to claim that women are broader because they evolved for reproduction as if men didnt. Conspicuous sex differences in our bodies lead to assumptions about gender differences. They feed our narratives about what a man is and what a woman is, and what our different roles in society should be. These myths about human nature havent exactly worked wonders for women and they fuel toxic masculinity.

Dunsworth, a biological anthropologist, sees it as her job as a professor and researcher to overturn outdated and false evolutionary traditions and to retell origin stories that are inclusive and unbiased.

We make meaning out of human evolutionary origin stories, she says. Whether they really dig human evolution or not, people are using it to make sense of the world and theyre thinking that some of these very narrow, very outdated ideas are the science, are the facts, she says. There are facts and then there are stories we tell about them. But we can improve our stories. There are more inclusive stories to tell, more complicated, more dynamic, more interesting, more scientific ways of describing the facts and telling stories about those facts.

Despite their flaws, theories of sexual selection for height and natural selection for pelvis size continue to be taught in classrooms, Dunsworth says, even in hers.

Weve taught it for years because theres an obsession with comparing the degree of difference between men and women to the much larger difference between male and female gorillas. Somehow, its supposed to show that we are more peaceful and more cooperative, while still acknowledging that, because human men are bigger than women, the big men in our ancestry have been the big winners, she says. I was teaching sexual selection. Its canon. I thought this is how we explain this until I sat back and thought it through.

Dunsworth had doubted the use of sexual selection to explain male and female body size differences. But the tipping point came in 2016 after she took exception on social media to comments by a well-known evolutionary biologist who was defending the theory in a politically charged rant.

Im a feminist and Im trying to be part of this inclusive, diverse future of the world, Dunsworth says. I knew that this one simple, narrow story wasnt even scientific. So, I spoke out. Thats when I realized this is a huge problem.

She started her research immediately and submitted her paper in 2018 for peer-review in Evolutionary Anthropology. Already available online, it appears in the May/June issue of the journal.

To have this new way of thinking in a major journal in my field and reviewed by my peers is the gold standard of knowledge, she says. Its not just me on my blog, raising my feminist fist in the air. This is how you advance knowledge.

Continued here:
URI anthropology professor challenges evolutionary narratives of big, competitive men and broad, birthing women - URI Today

Recommendation and review posted by Bethany Smith

More than 4,000 high-quality French breeding pigs have been transported to China. | Image: Unsplash  |  Photo Credit: Representative Image

Beijing: Over 4,000 high-quality French breeding pigs have been transported to China in six planes so far this year. China is rushing to restock imports after an outbreak of African swine fever swept through the country from late 2018. The fever killed tens of millions of pigs and reduced the sow herd by about 60 per cent.

The farmers who had stopped buying pigs have resumed orders due to soaring pork prices and a government drive to rebuild. Some farmers are doubling contracts that had been signed before the outbreak of the disease.

"Its like after World War Two. They lost half the herd and need to repopulate fast to get it back," Marie Pushparajalingam, global strategist for French swine genetics company Axiom, told Reuters.

China is importing breeding pigs to get the advantage of traits such as increased productivity and better meat quality that global genetics firms select for during breeding. A top breeding sow (female pig primarily used for breeding) can have a litter of as many as 16 piglets.

Axiom sent two 777 jets to China in January and two 747s were sent last month, totalling about 3,400 pigs. Pushparajalingam said that deals for six more plane-loads have been signed. The company is expecting additional business.

Another herd of 500 pigs bred by Dutch firm Topigs Norsvin arrived from France in southwestern Guizhou last week, Chinas Dekang Group said. The pigs will be in a nucleus breeding farm to produce 20 million pigs for slaughter.

China slaughters about 700 million pigs every year to produce over 50 million tonnes of pork. However, the disease outbreak reduced pork output by 21 per cent in 2019, leading to soaring prices. Production will fall again this year.

Due to the severe shortage of sows, producers are even holding back female pigs which are usually destined for slaughter to be used in breeding farms. These pigs will produce much smaller litters than a sow.

According to the estimates of a genetics company, China may need over 150 planeloads of pure bred pigs to replenish its herd.

The pigs undergo a month of health checks and spend another 30 days in quarantine under the observation of an official Chinese vet before shipment. Once they are transported, the pigs spend another 45 days at a quarantine facility to ensure that they are disease-free.

Laurent Poussart, manager of Francexporc, a pig freight specialist, said that the coronavirus pandemic has further complicated the shipments.

See the rest here:
'Pigs can fly'! Jumbo jets carry world's biggest hog herd from France to China - Times Now

Recommendation and review posted by Bethany Smith

One day not long before I turned 12, I got my first migraine. I was triumphantly competing for my primary school in a regional cross-country race when zig-zags of neon light began to buzz in my peripheral vision.

Then suddenly they were gone replaced by swathes of nothing, like Photoshop had just chopped out chunks of the path ahead. The race ended with me projectile vomiting into a garbage bin by the side of the road.

That afternoon, I cowered in a bedroom back at home, enduring a headache that no standard painkiller could touch.

When my mother took me to the doctor soon after, I described in detail the crazy vision, the pounding headache, the dramatic vomit and the next two days spent tiptoeing around dark rooms as the slightest vibration or sliver of light threatened to set things off again.

"Welcome to the world of migraines," said the GP, who had seen it all before.

Migraine sufferers, or "migraineurs" as they're termed, get pretty antsy when anyone with a bad headache calls on this diagnosis. Those of us who have experienced one know (as the clich goes) this is far, far more than a headache.

But the story of migraine isn't just a tale about the mistaken identity of pain.

For many it is a story of chronic disability and economic loss, it affects women three times more often than men and the latest research has drawn unsettling links to the risk of everything from depression and endometriosis to an increased chance of stroke.

Yet research funds are extremely difficult to come by and as a result, precisely how genetics, hormones and lifestyle interact to cause migraine, let alone universally effective treatments, is still being worked out.

Migraine is a mysterious condition and yet surprisingly common. About 12 per cent of Australians have experienced one and migraine makes a lot of top 10 lists: it is the world's most frequently diagnosed neurological problem; a leading cause of disability in Australia and the third most-common medical problem globally behind a hole in the tooth and a standard headache.

In 2018 alone the economic cost to Australia was estimated at more than $35 billion.

Like me, Lyn Griffiths got her first migraine as a child. But her mother suspected immediately what was up because she suffered from migraines too. When Griffiths' son started complaining of head pain at five years old, it didn't take long to join the dots.

But there's more to Griffiths' story than her family link to migraine.

She is better known as Professor Lyn Griffiths, a molecular geneticist and the executive director of the Institute of Health and Biomedical Innovation at the Queensland University of Technology, where she has pioneered international research into migraine and DNA.

"About 50 per cent of the time people who suffer from migraine have another close relative that also suffers," says Griffiths. "It was pretty obvious that there was a strong genetic component and as a geneticist with migraine in my own family that was interesting to me. I thought someone ought to be looking at this from a genetics perspective."

In 1998 Griffiths' research found the first gene linked to migraine. Since then genes responsible for two kinds of migraines including a deeply traumatic version known as a hemiplegic migraine that can cause paralysis and even coma have been discovered.

The genes for hemiplegic migraine are "heritable and causative", she says. That means if you have them you will definitely get this very severe form of migraine and can pass the gene mutation to your children who each have a 50 per cent chance of developing migraine too.

But the second and more common migraine is no walk in the park. Sure, sufferers don't lose consciousness, but they don't escape the hallmark pounding one-sided headache, light and sound sensitivity and nausea. For 20-30 per cent in this group, like me, there is also what's known as an aura causing vision changes and sometimes speech disturbances

Raphaella Crosby suffers from hemiplegic migraine. During an attack she typically loses her vision and become paralysed down one side of her body.

"What happened to me seemed too intense to be a migraine and it took me years to accept it," says Crosby, who had her first attack at 22. "It felt like my body was malfunctioning in really strange ways, I couldn't see, couldn't speak, couldn't lift my arms and parts of my body were numb."

An attack in 2012 put her in hospital for 10 days. After tests for everything from multiple sclerosis to lupus, the diagnosis was migraine.

"I didn't really recover from that point on," says Crosby, now 43. For the next seven years the migraines came one after another "until they all blurred into one".

Migraine cost Crosby her career, her friendships and any chance of a normal relationship. Eventually she took a disability pension and started using opiates to cope with the pain. "Things got really bad and I was going to hospital regularly," she says. "You get to a point where it's migraine all day, every day. I would often be completely paralysed and require care. I had to concede defeat to the beast."

Then 16 months ago something miraculous happened. Crosby joined the trial of a new class of drugs developed from the research of people like Griffiths. These drugs work by suppressing a peptide that soars in migraine patients during an attack.

Crosby's response to the medication was lifechanging. "I'm a super responder," she says of the monthly injections of a substance called erenumab-aooe, which is not a silver bullet for most people. "Only about 25 per cent of people respond as well as me and it's transformative because I thought I was totally and permanently disabled."

But there's a catch. The drug one of five in a new crop of similar medications that target and suppress calcitonin gene-related peptides, or CGRP is not listed on the Pharmaceutical Benefits Scheme.

Crosby received it for free while she was on the trial but now pays $695 a month to continue treatment. It's a big outlay for someone who is only just trying to rebuild a working life.

She has sold assets to pay for the medication over the next few months and is nervous about giving up the only effective treatment she has ever found.

"Where I'm at now is thinking about going back to work, knocking out my PhD, having a life again," she says. "I'm making friends. Life is good."

In the past 20 years at least 50 genes have been found that to relate to migraine.

But the complex web of influences that lead someone to actually suffer an attack are yet to be fully unravelled.

Instead, experts like Griffiths and Melbourne-based neurologist Tissa Wijeratne talk about "susceptibilities" and "triggers", as well as causes.

Migraines have long been associated with eating things like chocolate or drinking red wine. "We think certain perfumes, certain foods and even barometric pressure changes can be the triggers for those who are genetically predisposed," Griffiths says.

For Crosby, while her genes drive the condition, her triggers include dust and preservative 202, potassium sorbate, which is often found in things like yoghurt and sparkling wine. Crosby calls it "my kryptonite": "If I have even the slightest amount, I'm in all kinds of trouble".

Archaeologists have found references to migraine in ancient human civilisations and yet there seems to be no evolutionary benefit to maintaining migraine susceptibility in human DNA. I asked Griffiths why she thinks it hasn't been bred out of us.

She points to the work of Harvard neurologist Elizabeth Loder who has hypothesised that in fact there was a benefit. If migraine was triggered by an incoming storm or an approaching herd of wild animals then the migraineur hiding in the back of the cave had a survival advantage.

I grew out of my childhood migraines but a few years ago, soon after the birth of my third baby and quite out of the blue, I had another episode.

This time a peculiar numbness crept across the tips of my fingers on one hand and when I tried to speak only gibberish came out. I could not read or write as words and letters bounced all over the page. A short time later I experienced a ferocious headache. And there was vomiting.

"I suspect you'd like a scan of your brain?" the doctor deadpanned when I went for a check-up. The all-clear meant one thing was most likely: the migraines were back.

As an illness that affects 18 per cent of women but only 6 per cent of men, Wijeratne says it's a given that female hormones are also one of the culprits. This helps explain why migraine is linked to things like endometriosis and often emerges during puberty, childbirth and menopause.

It is possible that some of the gene mutations related to migraine risk are passed on by the X chromosome, Griffiths says, and because women carry two copies of X, their risk of inheriting the condition is higher. She is also researching how mitochondria, which are inherited maternally, may also potentially pass on genes involved in susceptibility to migraine.

Wijeratne specialises in treating migraine and is a sufferer himself. He began his career working with stroke patients but soon realised that many who turned up for treatment were what he calls "stroke mimics" like Crosby, not suffering from stroke at all, but migraine.

Wijaratne now has around 17 different medications to choose from when treating patients ranging from triptans to CGRPs, but he says coming up with an effective dose and combination remains trial and error.

Part of the reason for this, he believes, is a lack of funds for research. Migraine research attracts just 0.07 per cent of medical funding, says Wijaratne.

Griffiths sighs in frustration when funding is mentioned. "It's the hardest thing in the world to get funding for migraine research," she says. "It's one of the most common neurological disorders and yet one of the lowest on the scale for funding to support research."

Wijaratne agrees: "It has links to every human health condition under the sun including cardiovascular disorders," he says, emphasising that migraine patients take their own lives two-to-three times more frequently than the wider population.

"Migraine is definitely the most neglected, worst managed and most under-recognised medical disorder worldwide, wherever you are," he says. "If you have cancer, multiple sclerosis, Parkinson's disease or stroke, you can actually see the disability. If you suffer from migraine you can't see anything although the suffering is unbelievable high."

This is a comparison Crosby can relate to having also experienced what she describes as "a minor skirmish with breast cancer".

"People find it very confronting when I say that breast cancer was nothing compared to migraine," she says, explaining that the emotional and medical support she received as a cancer patient far exceeded her experiences with migraine treatment. "I don't say it a lot because I don't want to offend people who have had very difficult battles with cancer but mine was caught early, dealt with and off I went."

Wijaratne encourages patients to use therapeutic treatments ranging from acupuncture and Botox injections to meditation and yoga all of which have scientific studies supporting effectiveness in some patients, he says.

Neuromodulation in which electric currents are used in the brain is a newer treatment with promise.

And so are "nutriceuticals", where vitamins not pharmaceuticals are used to supplement deficiencies that are now known to kick off a migraine. These include vitamin B2, magnesium and Q10, but one of the most promising is folate, a B-group vitamin that is found in green leafy vegetables.

A mutation on the gene methylenetetrahydrofolate reductase (known as MTHFR) can make carriers susceptible to migraine with aura, Griffiths says, and this gene reacts strongly to folate levels in the diet.

MTHFR is also what Griffiths calls a "susceptibility gene" for stroke and may help to explain the migraine-stroke link.

The stroke risk underscores the importance of a healthy lifestyle if you are a migraine sufferer, says Wijaratne.

"If you are a patient with migraine and visual aura then the increased stroke risk is small," he says. "However, if you add any other risk factor. Let's say you pick up smoking, or don't eat well, don't sleep well, don't maintain blood pressure, then your risk goes up as much as 12 times."

Some patients don't respond to existing treatments, Wijeratne says, but he is adamant "one should never lose hope".

"If a doctor says 'I've tried everything', then choose a different doctor. You should always be hopeful."

Raphaella Crosby is a founding member of patient advocacy group Migraine Australia.

Excerpt from:
Migraines strike women three times more than men, and we're finally starting to understand why - ABC News

Recommendation and review posted by Bethany Smith

Breastfeeding your baby can help reduce the risk of the following cancers in women:Breast CancerBreastfeeding can slightly lower a womans risk of breast cancer. Breastfeeding reduces a womans number of menstrual cycles thus decreasing a womans exposure to hormones like estrogen. Estrogen production can be a factor in the growth of breast cancer cells.

Ovarian CancerBreastfeeding may reduce a womans risk of developing ovarian cancer due to the delay of ovulation. The more a woman ovulates, the more the risk of cancer cell mutation that could trigger the onset of ovarian cancer.

Parrish Medical Center cares for women in every stage, whether through supporting a healthy pregnancy, diagnosing and treating disease or easing the transition to menopause. Parrish Medical Centers team-based care philosophy ensures your concerns will be heard, understood and treated appropriately.

PMCs Womens Care provides a full range of gynecologic services, from routine medical screenings and treatments to gynecologic surgery, oncology and health navigation services.

If you would like more information about how breastfeeding can help improve your overall health and reduce your risk of certain cancers, visit parrishhealthcare.com or call 321-268-6682. Our team of health care professionals is here to answer all of your questions and ease your concerns.

Continued here:
The Health Benefits of Breastfeeding | Parrish Medical Center - SpaceCoast Living

Recommendation and review posted by Bethany Smith

Mood, diet and lifestyle habits, and vitamin D status are all closely connected. Low vitamin D may trigger low mood, making it more difficult to sleep, eat well, and exercise regularly, says Choukri. Yet, she adds, These difficulties may be due to the mood itself rather than vitamin D.

On the flip side, research suggests that not getting enough sleep, having a poor-quality diet, and inactivity can contribute to low mood independently, regardless of vitamin D status.

Heres a closer look at the relationship among vitamin D status, these habits, and mood and health.

RELATED: 8 Smart Tips for Successfully Managing Stress

Theres a scientific link between getting adequate vitamin D and sleeping well, which plays a role in mood on its own. Vitamin D is important in the process of making serotonin, and you need serotonin to make melatonin, says Dr. Greenblatt. Melatonin is a hormone that promotes sleep, according to the Mayo Clinic.

A meta-analysis published in October 2018 in the journal Nutrients concluded that vitamin D deficiency is linked with a higher risk of sleep disorders.

Its all connected: Lack of sleep alone, regardless of vitamin D status, may contribute to depressive symptoms, along with anxiety, notes the National Sleep Foundation. According to the Mayo Clinic, symptoms of depression may include tiredness and a lack of energy, sleep disturbances like insomnia, and a loss of interest in pleasurable activities.

RELATED: The Relationship Between Insomnia, Anxiety, and Depression: Its Complicated

Low mood from vitamin D may make someone less likely to be active, says Penckofer. And inactivity can trigger a vicious cycle that further contributes to low mood. A study published in April 2019 in the International Journal of Environmental Research and Public Health found that sedentary behavior and low physical activity were linked to anxiety and depression. And a review published in June 2015 in Cognitive Behavior Therapy found that exercise can even help reduce anxiety symptoms and bad mood, the authors noted. Another study, published in September 2018 in The Lancet Psychiatry, found that all types of exercise from walking to cycling were associated with improved mental health.

According to the Mayo Clinic, exercise boosts endorphins, gets your mind off stressful situations, gives you confidence, and can provide social interaction.

Improving vitamin D status may improve mood, helping you to get out the door and move more.

Vitamin D may also independently offer benefits for physical health. A study published in July 2018 in the Journal of Orthopaedic Science found that for elderly people, exercise and taking a vitamin D supplement each on their own helped improve muscle mass and physical function. Therefore, getting the vitamin D you need not only boosts mood and may help compel you to move more, but it also may help you get more out of your workout.

RELATED: Why Exercise Boosts Mood and Energy

Research suggests a vitamin D deficiency is more prevalent in people with obesity. One smallstudy, published in July 2018 in the International Journal of Preventative Medicine, found that obese people who supplemented with a high dose of vitamin D for six weeks decreased their weight, body mass index (BMI), waist circumference, and hip circumference significantly.

Obesity is a complex disease: Both genetics and daily lifestyle habits affect risk, past research suggests. Yet having low mood, potentially due to vitamin D deficiency, may make you more likely to reach for potato chips or that bag of cookies rather than healthier choices, like carrot sticks or an apple. You can blame cortisol, the stress hormone, which can cause you to overeat when youre feeling emotional distress, according to Harvard Medical School.

What you eat similarly impacts mood, just like your sleep and exercise habits. For example, previous research suggests that chamomile may provide a soothing effect by producing more of the feel-good chemicals dopamine and serotonin. Carbohydrates can also boost the production of serotonin, according to the Massachusetts Institute of Technology (MIT), though make sure youre choosing healthy, whole grain options, rather than refined carbs like cookies and crackers.

Meanwhile, poor food and drinkchoices can contribute to low mood. Take sugar: Astudy published in July 2017 in Scientific Reports found that eating too much refined sugar could up your risk of depression. So, too, may caffeine and alcohol bring down your mood, according to the Mayo Clinic and past research, respectively.

RELATED: The Ultimate Diet Plan for a Happier, Less-Stressed You

Skimping on D may seem like no biggie in the grand scheme of things, especially in the time of COVID-19, but prioritizing getting enough of the sunshine vitamin is critical for your long-term health.

We do see deficient vitamin D levels are related to many different diseases type 2 diabetes, Alzheimers disease and dementia, and [some] types of cancers, says Mary Byrn, PhD, RN, associate professor in the Marcella Niehoff School of Nursing at Loyola University Chicago. Therefore, treating deficient vitamin D levels is not harmful, and I would recommend that everyone work with a healthcare provider to reach sufficient vitamin D levels.

The Cleveland Clinic also notesthat a vitamin D deficiency can cause other physical health issues, like osteoporosis and osteomalacia, and can even impact your nervous system and immune system, which is the last thing anyone needs during a pandemic like the current one.

RELATED: Can Supplements Protect Me Against the New Coronavirus?

Follow this link:
Are You COVID D-Prived and Down? How Low Vitamin D Can Cause Low Mood - Everyday Health

Recommendation and review posted by Bethany Smith

Perchlorate-induced natrium-iodide symporter (NIS) interference is a well-recognized thyroid disrupting mechanism. It is unclear, however, whether a chronic low-dose exposure to perchlorate delivered by food and drinks may cause thyroid dysfunction in the long term. Thus, the aim of this review was to overview and summarize literature results in order to clarify this issue.Authors searched PubMed/MEDLINE, Scopus, Web of Science, institutional websites and Google until April 2020 for relevant information about the fundamental mechanism of the thyroid NIS interference induced by orally consumed perchlorate compounds and its clinical consequences.Food and drinking water should be considered relevant sources of perchlorate. Despite some controversies, cross-sectional studies demonstrated that perchlorate exposure affects thyroid hormone synthesis in infants, adolescents and adults, particularly in the case of underlying thyroid diseases and iodine insufficiency. An exaggerated exposure to perchlorate during pregnancy leads to a worse neurocognitive and behavioral development outcome in infants, regardless of maternal thyroid hormone levels.The effects of a chronic low-dose perchlorate exposure on thyroid homeostasis remain still unclear, leading to concerns especially for highly sensitive patients. Specific studies are needed to clarify this issue, aiming to better define strategies of detection and prevention.

PubMed

The rest is here:
Interference on Iodine Uptake and Human Thyroid Function by Perchlorate-Contaminated Water and Food. - Physician's Weekly

Recommendation and review posted by Bethany Smith

Chrissy Teigen announced on social media today that she successfully underwent surgery to remove her breast implants after having them for 10 years.

On May 26, the cookbook author announced her upcoming surgery plans, which required a coronavirus test prior to the procedure.

The two Luna originals say "Have fun pulling your boobies out Love Luna," and "Bye boobies," with a mermaid sticker attached.

Advertisement

"They've been great to me for many years but I'm just over it. I'd like to be able to zip a dress in my size, lay on my belly with pure comfort! No biggie! So don't worry about me! All good. I'll still have boobs, they'll just be pure fat," Teigen wrote on Instagram.

"Life-changing, you're gonna love it. I got mine out last year," Curry commented on Teigen's initial announcement post.

Michelle Visage and Yolanda Hadid have also been vocal about their decisions to have their breast implants removed.

View post:
Chrissy Teigen had her breast implants removed after 10 years, and her daughter wrote a hilarious note to cele - Business Insider India

Recommendation and review posted by Bethany Smith

Endometriosis Market Forecast 2020-2026

The Global Endometriosis Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Endometriosis Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/73643

The Report Covers the Following Companies:AbbVieAstraZenecaBayer HealthCarePfizerAddex TherapeuticsAstellas PharmaDebiopharmElexoPharmEndoCeuticsEuroscreenForendo PharmaKissei PharmaceuticalNeurocrine BiosciencesNippon ShinyakuTakedaBayer AGNeurocrine Biosciences

By Types:Gonadotropins Releasing Hormone AgonistsNon-Steroidal Anti-Inflammatory DrugsProgestinOral Contraceptive Pills

By Applications:Hospital UseClinic UseOther

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/73643

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Endometriosis Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/73643

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail Alex@UpMarketResearch.comOrganization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

View original post here:
Endometriosis Market Analysis With Key Players, Applications, Trends And Forecasts To 2025 - Surfacing Magazine

Recommendation and review posted by Bethany Smith

Dermatologist Dr. Sandra Lee tugged, snipped, and cut at a lipoma for over 40 minutes to try and remove it from a woman's back in a recent YouTube video posted June 4 to her infamous channel, "Dr. Pimple Popper."

The lipoma or lump caused by slowly overgrowing fatty tissue was particularly difficult to remove because of its "bubbly" nature. The lump was dispersed through different parts of a large area on her back, making it harder to remove than a lump all in a singular area.

To make sure all of the fatty tissue was gone, Lee zapped the area with a cauterizing instrument to stop any bleeding caused during the extraction process. Once all of the tissue had been removed, the skin flap that laid over the incision was visibly flatter.

Advertisement

"Now my hand's gonna shake because I've been squeezing you so hard," Lee said as she sutured her patient's large incision.

Watch Dr. Pimple Popper remove a 9-pound lump that was growing on a man's arm for nearly a decade

Dr. Pimple Popper reveals her nighttime skincare routine, and it only includes 3 steps

Go here to read the rest:
Dr. Pimple Popper removed a 'big bubbly' lump from a woman's back by tugging, snipping, and cutting for over 4 - Business Insider India

Recommendation and review posted by Bethany Smith

Hollings Cancer Center researchers at the Medical University of South Carolina (MUSC) and colleagues assessed the connection between dietary advanced glycation end products (AGEs) and breast cancer risk in a study first published online March 2020 in Cancer Prevention Research.

It supports an increasingly evident link between high levels of AGEs in the body and cancer risk, said principal investigator David Turner, Ph.D., who worked with colleagues Susan Steck, Ph.D., with the University of South Carolina, and Lindsay Peterson, M.D., with Washington University School of Medicine.

The study was part of a larger decade-long prostate, lung, colorectal and ovarian cancer screening trial (PLCO) designed and sponsored by the National Cancer Institute. It included over 78,000 women between the ages of 55 and 74 years who were cancer free at the start of the study. The women completed a food frequency questionnaire at the beginning and again at five years into the study. After an average of 11 years, 1,592 of the women were diagnosed with breast cancer. When the intake of high-AGE food was assessed, based on the questionnaires, increased AGE intake via the diet was associated with an increased risk of in situ and hormone receptor positive breast cancers.

Advanced glycation end products are proteins and lipids (fats) that go through a chemical alteration called glycation when they are exposed to sugars. This process occurs naturally in the body. However, processed foods and foods cooked at high temperatures are extremely high in AGEs, which can lead to a dangerous overabundance in the body.

Turner said AGEs are involved in nearly every chronic disease, in some way. The study of AGEs in cancer is just starting to get traction. The presence of AGEs has been known for at least 100 years, but the research has been challenging. In order to determine how they work, their mechanism of action, researchers first have to determine a role in various diseases.

Turner said this study is important because it adds to the evidence between high levels of AGEs in the body and cancer risk. Turner and his collaborators are promoting the connection between AGEs and lifestyle choices to help the public make better food choices.

This will become an even more popular area of study as researchers employ new tools to help study AGEs. A novel device, the AGE reader, is about to change how we look at AGEs in the clinic, Turner said. The AGE reader, made by Diagnoptics, is an easy to use noninvasive device where someone rests their forearm for just 12 seconds. It uses light at certain wavelengths to excite AGE autofluorescence in the human skin tissue.

This machine actually measures glow from some of the AGEs. The more AGEs that are in the skin, the higher the glow, explained Turner.

While the AGE reader has been used to show strong correlations between AGE levels and Type 2 diabetes, cardiovascular disease and even mortality, Turner is using a cancer center support grant to validate further the AGE reader for use in cancer patients. He and his colleagues plan to investigate whether pigmentation in the skin skews the reading and use the reader as part of a growing community outreach program.

Since a link between AGEs and breast cancer has been shown, the ultimate goal is to test all Hollings Cancer Center patients who are interested at each visit, Turner said. This will provide a huge amount of data about the link between AGEs and a wide variety of cancers. Turner and his collaborators expect that future multicenter grants will come out of this project.

While the connection between high AGE levels and cancer risk might be disconcerting, research is also being done to determine if there is a way to reverse the detrimental effects of AGEs.

Bradley Krisanits, a Ph.D. student in Turners lab, said that preliminarily, they have seen that physical activity reduces the amount of AGEs in the circulation.

In our prostate cancer models, we see that physical activity counteracts prostate cancer progression in mice fed a high-AGE diet. This may be occurring due to a reduction in AGEs and changes in the immune system that we need to study more.

Turner hopes that by educating people about AGEs, they can make informed lifestyle decisions and lower their risks for chronic diseases. The top three things that a person can do is learn what AGEs are, avoid processed foods and think about how you cook your food in order to make changes to avoid the highest AGE-inducing cooking methods such as frying, grilling and broiling.

AGEs build up in a cumulative way. Fats, sugars, everything that is bad for you leads to the accumulation of AGEs. One of our goals at Hollings is to reach out to the community to encourage the public to make healthier choices. Just making small changes in your diet can have a big effect.

Read the original here:
Study links elevated levels of advanced glycation end products with breast cancer risk - Mirage News

Recommendation and review posted by Bethany Smith

On Friday, June 5, a few days after World MS Day on May 30, there was a day of online conferences and workshops to learn more about multiple sclerosis. It was an opportunity to shed light on autologous bone marrow transplantation, a little known treatment that could cure multiple sclerosis.

Neuron

Multiple sclerosis (MS) is a neurodegenerative autoimmune disease that causes stiffness, pain, and fatigue. It is the main cause of disability, exclusion from the labor market, and social exclusion among young people, as it occurs mainly among people between 25 and 35 years old. According to the National MS Society, approximately 1 million people in the United States suffer from MS.

Currently, there is no treatment to cure MS, but there is hope: Autologous bone marrow transplantation or autologous hematopoietic stem cell transplantation. This treatment allows patients to go from the more common forms of multiple sclerosis into remission. If carried out early enough, it enables at least partial recovery from the disability.

Read Also: Combo of Diabetes and Hypertension Drugs Causes Cancer Cell Death, Researchers Find

The aim of this treatment is to rebuild a new immune system in patients. This includes intensive chemotherapy followed by reinjection of the patients hematopoietic stem cells. Several studies conducted between 2015 and 2019 on this technique have shown that 83.3 of patients with the relapsing-remitting form had no attack in the four years following auto-transplantation and three years after transplantation 78% of patients with secondary progressive multiple sclerosis and 66% of patients with primary progressive multiple sclerosis experienced no worsening of their disability, Mediapart continues.

One of the main obstacles to this treatment remains the difficulty of access. Many patients testify that their neurologist often finds this method too experimental and too risky. Another factor that discourages the use of autologous bone marrow transplantation is the risk-benefit ratio, which is considered unbalanced. Transplant-related mortality is between 5 and 10%, which justifies doctors preference for a treatment that is considered safer.

Read Also: Diabetes: Metformin Transfers Blood Sugar From the Blood to the Intestines

Another treatment has shown encouraging results in multiple sclerosis. This is a drug for diabetes, metformin, which rejuvenates stem cells to convert them into myelin-producing cells and thus help combat multiple sclerosis. These results have been published in the journal Cell Stem Cell, and it is expected that the tests, which are currently only carried out on mice, will also be carried out on humans within a year. I am very optimistic, study author Professor Robin Franklin told The Guardian newspaper.

References

Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells

https://blogs.mediapart.fr/noelle-tassy/blog/300520/journee-mondiale-de-la-sep-et-si-parlait-du-traitement-dont-ne-parle-pas

Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents

Read the original:
Autologous Bone Marrow Transplantation and Metformin, a Hope for the Cure of Multiple Sclerosis - Gilmore Health News

Recommendation and review posted by Bethany Smith

Management to Host One-on-One Investment Meetings

NEW YORK, June 11, 2020 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST, during theRaymond James Human Health Innovations Conference, a virtual event connecting institutional investors with company management teams that will be held June 15-18, 2020.

Mr. Lebovits and Dr. Kern will update conference participants on the Company's investigational therapeutic, NurOwn, that is currently in a fully enrolled phase 3 study for the treatment of ALS and a phase 2 study for the treatment of progressive multiple sclerosis. Additionally, they will present an overview of the Company's financial position and pipeline. After the presentation, the management team will participate in a question and answer session with institutional investors.

Mr. Lebovits and Dr. Kern will be joined by David Setboun, PhD, MBA, Chief Operating Officer, Stacy Lindborg, PhD, Head of Global Clinical Research, and Preetam Shah, PhD, MBA, Chief Financial Officer, for a series of one-on-one meetings, with select institutional investors arranged by Raymond James.

Participants can view the presentation via the event link and those unable to join will have access to an archived link on the Company's Events and Presentation webpage after the conclusion of the conference.

EVENT: Raymond James Human Health Innovations Conference

PRESENTATION: Thursday, June 18th at 9:00 am EST

LINK: https://bit.ly/2YmZf8u

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently receivedU.S.FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began inMarch 2019.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment inMarch 2019.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: +1-862-397-1860pshah@brainstorm-cell.com

Media:

Sean LeousWestwicke/ICR PRPhone: +1-646-677-1839sean.leous@icrinc.com

View original content:http://www.prnewswire.com/news-releases/brainstorm-to-present-at-the-raymond-james-human-health-innovations-conference-301074370.html

SOURCE Brainstorm Cell Therapeutics Inc

Visit link:
BrainStorm to Present at the Raymond James Human Health Innovations Conference - Yahoo Finance

Recommendation and review posted by Bethany Smith

The company said the move was aimed at the development of next generation cellular immunotherapy FLASH-CAR technology

(), a clinical-stage developer of cell-based technologies and therapeutics, announced Thursday that it has struck a three-way material transfer agreement (MTA) with Weill Cornell Medicine in New York City and the companys strategic partner, Arbele Limited.

With this agreement, Avalon GloboCare and Arbele Limited intend to collaborate with Weill Cornell Medicine and co-develop the standardized laboratory steps necessary to generate clinical-grade CAR-T and CAR-natural killer (NK) cells for use in future human clinical trials with Avalons first FLASH-CAR platform candidate, AVA-011.Similar to T-cells, NK cells are a type of white blood cell, also able to attack cancer cells, but utilize different mechanisms.

The company said this process development step will provide the bridge between Avalons benchtop research and the bio-manufacturing processes to potentially deliver the clinical-grade cellular immunotherapy product to patients.

READ:Avalon GloboCare advancing immune cell therapy to treat blood cancers using FLASH-CAR technology

We are excited about this agreement to translate our cellular therapy candidates into standardized, clinical-grade cell products that could be used in future clinical trials, Avalon GloboCare CEO David Jin said in a statement.

This step reflects our dedication to establishing an infrastructure to develop our cellular immunotherapy candidates and to maintain the highest possible standards for generating clinical-grade cells for human cancer trials, he added.

AVA-011 is a next generation cellular immunotherapy candidate using Avalons FLASH-CAR technology that targets both CD19 and CD22 tumor antigens on cancer cells. Avalon has already successfully completed pre-clinical research on AVA-011, including tumor cytotoxicity studies.

Avalon expects to begin a first-in-human clinical trial with AVA-011 for the treatment of relapsed or refractory B-cell lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma in the first quarter of 2021. The goal is to use AVA-011 as a bridge to bone marrow stem cell transplant therapy, currently the only curative approach for patients with these blood cancers.

Avalons next generation immune cell therapy using FLASH-CAR technology is being co-developed with the companys strategic partner Arbele Limited. The adaptable FLASH-CAR platform can be used to create personalized cell therapy from a patients own cells, as well as off-the-shelf cell therapy from a universal donor, expanding the reach of cancer patients that can be treated.

Avalon, based in Freehold, New Jersey, specializes in developing cell-based technologies and is involved in the management of stem-cell banks and clinical laboratories.

Contact the author Uttara Choudhury at [emailprotected]

Follow her on Twitter: @UttaraProactive

See the original post here:
Avalon GloboCare strikes three-way material transfer agreement with Weill Cornell Medicine and Arbele Limited - Proactive Investors USA & Canada

Recommendation and review posted by Bethany Smith

The Hematopoietic Stem Cell Transplantation (HSCT) Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Hematopoietic Stem Cell Transplantation (HSCT) market report covers the worldwide top manufacturers like (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Hematopoietic Stem Cell Transplantation (HSCT) market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Hematopoietic Stem Cell Transplantation (HSCT) Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Hematopoietic Stem Cell Transplantation (HSCT) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Hematopoietic Stem Cell Transplantation (HSCT) Market Background, 7) Hematopoietic Stem Cell Transplantation (HSCT) industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Hematopoietic Stem Cell Transplantation (HSCT) Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Autologous

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986

Geographically, the report includes the research on production, consumption, revenue, Hematopoietic Stem Cell Transplantation (HSCT) market share and growth rate, and forecast (2020-2026) of the following regions:

Important Hematopoietic Stem Cell Transplantation (HSCT) Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Hematopoietic Stem Cell Transplantation (HSCT) Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Hematopoietic Stem Cell Transplantation (HSCT) MarketSummary; MarketScopeGives A BriefOutlineof theHematopoietic Stem Cell Transplantation (HSCT) Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Hematopoietic Stem Cell Transplantation (HSCT) Market.

Hematopoietic Stem Cell Transplantation (HSCT) Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Hematopoietic Stem Cell Transplantation (HSCT) market?

To Get Discount of Hematopoietic Stem Cell Transplantation (HSCT) Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2276986

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

More:
Hematopoietic Stem Cell Transplantation (HSCT) Market Trends 2020: In-Depth Analysis of Industry Growth & Forecast Up To 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

Throughout the past decade, consumer biology tests have been all the rage. Companies such as 23andMe and Ancestry DNA have made their test kits accessible to every day Americans. One can screen for anomalies in their genetic code or identify their lineage. With recent advances in stem cell research, a new opportunity within the consumer biology market has appeared. Nabeel Quryshi, Michael Chen and Zeel Patel are three Harvard undergraduates who observed the unmet, rising demand of control over ones stem cells. They worked together to create Evera, the first at-home stem cell banking company. The three Harvard students are joined by the schools world-renowned biology professor, Dr. George Church. The Cambridge, Massachusetts-based company was incubated at the Harvard Innovation Lab, and has former NASA astronaut Scott Kelly as a investor.

Evera cofounders from left to right: Nabeel Quryshi, Michael Chen and Zeel Patel.

Kelly says, "I did a lot of my independent research, consulted with NASA physicians and scientists, and experts in the stem cell for cancer treatment fields. All those discussions and research indicated that this technology has merit."

Frederick Daso: What led you and your team to identify that stem cells could be potentially used to prevent neurodegenerative disease?

Nabeel Quryshi: I wouldn't single out a focus on neurodegenerative diseases. However, over the last decade, there has been a flurry of research around the use of stem cells to treat conditions such as Parkinson's, Dementia, Alzheimer's, etc. People are working on prevention, but there are two main use cases of stem cells currently. One is for treatment (replacement of damaged or lost cells), and the other is disease modeling (being able to model diseases and test the effects of new drugs completely in vitro without having to get a biopsy).

Daso: In the same ways that blood banks function, how did you manage to apply that concept to the storage of stem cells over a long time?

Quryshi: Cord blood banks and academic stem cell banks that use standardized cryopreservation protocols have been around for a while. The main innovation behind Evera was developing technology around the collection and preservation of urine-derived cells.

Daso: Why don't more mothers store their children's cord blood in stem cell banks? Is it mostly due to a price issue, or is there some other factor at play?

Quryshi: From the countless interviews we've done, it seems to be a price issue. Additionally, it's hard to make a sale around the time of birth as families have countless other things to worry about that are more immediate to the birth of a child.

Daso: What would be driving the growth of this market both now and in the future?

Quryshi: The growth of new cutting edge cell therapies is certainly further demonstrating the need for personal cell biobanking. Furthermore, the success of the direct to consumer genetic testing industry (23andMe, Ancestry, etc.) is a significant driver of growth. From the research we've conducted and the customers we have spoken to, individuals who have already taken 23andMe or another genetic test and know what they are at risk for genetically are looking for ways to take tangible action. Evera is that next step. Instead of just understanding what your future genetic risk is, Evera allows you to make a real biological investment in your future health and wellbeing. While knowing you're at risk for saying Parkinson's is excellent, being able to set aside your youngest cells so that one day you may be able to combat the effects of such a disease is terrific.

However, one should note that although the growth and technology coming from the cell therapy and stem cell therapy industry is astonishing, these are still projections. We have yet to see a fully FDA approved therapy that utilizes the specific types of stem cells we use (induced pluripotent stem cells). Nevertheless, by the time such treatments make it to the clinic, your cells will have aged significantly, and thus it makes sense to save them away now.

Daso: Could you walk me through the thought process of figuring out how to extract stem cells from urine? (From what I know, stem cells usually come from other parts of your body!)

Quryshi: Until around 2011/2012, you would have been right. However, utilizing the fantastic technology that comprised Dr. Yamanaka's 2006 Nobel Prize, scientists have been able to convert any cell in the human body to a kind of stem cell called an induced pluripotent stem cell. This cell has the capability of being able to differentiate into any cell type in the human body. We have advanced tech around the conversation of urine-derived cells to these iPSCs.

Daso: How have you designed your D2C service to ensure that a customer's DNA and associated data are not at risk?

Quryshi: We take data and privacy extremely seriously. We are well aware of the concerns people already have to D2C genetics products. To ensure the confidentiality and privacy of your data and sample, we separate your personally identifiable information from sample information and simultaneously use multiple layers of encryption and cryptography. Your sample and associated data cannot be associated with you individually. Furthermore, our facility is monitored 24/7 with top of the line security measures. We believe that your sample is your property.

Daso: What was the turning point during your undergrad to pursue this idea?

Quryshi: Having worked at 23andMe, I was able to get the lucky opportunity to be a part of arguably the world's most successful consumer genetics company. I saw first hand the benefits of providing customers with their genetic risk. Yet, I discovered that merely providing such risk predictions may not be enough led me to found Evera on the notion that tangibly investing in one's future health and wellbeing through cell banking will propel us into the age of personalized medicine.

Daso: How do you leverage your advisory board to navigate regulations and moral hazards in this space?

Quryshi: We have assembled a dream team consisting of experts in stem cell banking and cell therapy. Our co-founders and advisors comprise of professors from Harvard and Stanford, executives from companies such as Verily as well as top grad students and postdocs in stem cell biology from Harvard and Stanford. We work collaboratively to make sure we adhere to all regulations and ensure the secure preservation of our customer's cells.

If you enjoyed this article, feel free to check out my other work onLinkedInand my personal website,frederickdaso.com. Follow me on Twitter@fredsoda, on Medium@fredsoda, and on Instagram@fred_soda.

See the article here:
Evera, A Harvard Consumer Biotech Company, Brings Stem Cell Banking To You - Forbes

Recommendation and review posted by Bethany Smith

A new market report by Market Research Intellect on the Direct-to-consumer Genetic Testing Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Direct-to-consumer Genetic Testing sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=239640&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Direct-to-consumer Genetic Testing manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Direct-to-consumer Genetic Testing Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=239640&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Direct-to-consumer Genetic Testing. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=239640&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Direct-to-consumer Genetic Testing market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See more here:
Direct-to-consumer Genetic Testing Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 -...

Recommendation and review posted by Bethany Smith

LOS ANGELES, June 10, 2020 /PRNewswire/ --Mesenchymal stem cells (MSCs) are multipotent in that they naturally replenish the cell types that build our bone, cartilage and adipose tissues. Their regenerative potential makes them exquisite candidates for cell-based therapies. However, clinicians often need to administer massive numbers of MSCs to reach sufficient numbers of cells that successfully engraft and remain functional over time.

Now, a new study in Advanced Functional Materials by a team at the Terasaki Institute for Biomedical Innovation in Los Angeles and the University of California, Los Angeles (UCLA) has reported a minimally-invasive approach, which deploys an array of "microneedles" that provide a bioactive depot of MSCs. By embedding MSCs in a gel-like material that prolongs their viability and functionality, and targeting damaged tissues with high spatial precision, the researchers showed their approach to accelerate wound healing in a mouse model with excised skin segments.

"Microneedles have been successfully used in the past to painlessly deliver drugs to target tissues such as skin, blood vessels and eyes. We demonstrate here with 'Detachable Microneedle Depots' that an analogous approach can deploy therapeutic cells at target sites," said co-corresponding author Ali Khademhosseini, the Director and CEO of the Terasaki Institute.

The team set out to investigate their microneedle concept in a mouse skin wound model in which a defined excision is made in the epidermal tissue layers. To be able to strategically place individual microneedles within the wound bed, a simple and effective deployment mechanism was devised by attaching an array of microneedles on a small strip of scotch tape with their pointed ends facing away from the tape. Precisely positioning the tape with its patterned microneedle surface on the wound, allowed the individual microneedles to penetrate into the wound bed. Then, the tape was peeled off, causing the microneedles to detach and remain embedded in the wound tissue.

"The concept would even be compatible with using patient-derived cells in more personalized device approaches," said Khademhosseini who is exploring further uses of this technology as part of the Terasaki Institute's research program.

The Terasaki Institute for Biomedical Innovation (terasaki.org) is a non-profit research organization that invents and fosters practical solutions that restore or enhance the health of individuals.

SOURCE Terasaki Institute

https://terasaki.org/institute/

Link:
Microneedling therapeutic stem cells into damaged tissues - PRNewswire

Recommendation and review posted by Bethany Smith

Dr. Rebecca Morris, leader of the Stem Cells and Cancer lab at The Hormel Institute, received a multi-year grant to study stem cells originating in adult bone marrow and their possible effects on skin diseases, including cancer. The grant, from the Nation Institute of Healths National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), awarded Morris with $373,688 over two years for her research project Identification of Novel Epidermal Progenitors.

Morris said this research is significant because it will contribute new understanding of epithelial biology, and blood and bone marrow in general, provide possible new targets for epithelial cancer prevention and control, validate liquid biopsy of blood as a diagnostic tool, and help her and her team to achieve their goal of preventing and alleviating chronic skin diseases including cancer, psoriasis, and epidermolysis bullosa.

Many years ago, I contributed basic research on identification and isolation of adult tissue stem cells from skin epidermis, and demonstrated their role in skin cancer initiation and promotion, Morris said. Now, I am again thrilled to be on the edge of discovery of a new population of epithelial stem cells and have the opportunity to determine their roles in regeneration and cancer.

Cells in the body that cover surfaces (like the epidermis, or top layer of skin) or line spaces (like ducts in mammary gland or lining of the colon) are called epithelial cells. In adults, most cancers originate from these epithelial cells. However, new research has identified certain bone marrow derived epithelial cells (BMDECs) in normal, healthy human subjects.

Morris and her team do not believe anyone has yet described the features and nature of these cells, or analyzed their function.

The research team has hypothesized that the epithelial cells from the bone marrow are epithelial stem cells. They therefore hope to demonstrate that BMDECs include a novel population of adult tissue stem cells that can be gathered to chronically compromised epithelium, such as skin cancer or psoriasis, and regenerate it.

Skin cancer is by far the most common type of cancer in the United States, with millions of people diagnosed each year. As we enter summer, it is important to remember simple steps like staying out of the sun during the middle of the day, staying in the shade, and wearing sunscreen can help reduce your skin cancer risk.

Next steps for Morriss research include determining how these blood borne epithelial cells are recruited to the skin, the recruiting molecules, how the recruitment can be good or bad, and how to modulate their recruitment to alleviate disease.

See more here:
Major skin cancer research study to begin at The Hormel Institute - Austin Daily Herald - Austin Herald

Recommendation and review posted by Bethany Smith

Noveome Biotherapeutics is a clinical-stage company focused on developing therapies for the regenerative repair of tissues. Their product ST266, a first-of-its-kind, multi-targeted, non-cellular platform biologic comprised of a complex mixture of biomolecules, is currently being evaluated as a potential treatment for the severe inflammatory response observed in the lungs of some COVID-19 patients.Technology Networks recently spoke with William J. Golden, Noveome Biotherapeutics Founder, Chairman and CEO, who explains the underlying basis for investigating ST266s potential against COVID-19. Golden also elaborates on many of the other indications for which ST266 is being developed to treat.Laura Lansdowne (LL): Could you provide our readers with a brief overview of Noveome Biotherapeutics?William J. Golden (WJG): Noveome is a clinical-stage biotherapeutics company located in Pittsburgh, PA. The company was founded in 2000 by Bill Golden and Lancet Capital. The group was interested in exploring non-embryonic stem cells and identified a technology at the University of Pittsburgh that was using cells derived from human amnion, a membrane that closely covers the fetus during development. The company, named Kytaron Technologies, Inc. at the time, licensed that amnion cell technology but, ultimately, Noveome scientists were able to discover, develop and patent their own unique population of cells, called Amnion-derived Multipotential Progenitor (AMP) cells, using a proprietary culture method that follows current Good Manufacturing Practice (cGMP) regulations. These novel cells were used to produce our product, ST266.LL: What is ST266? Could you elaborate on its mechanism of action in relation to the healing process?WJG: Noveomes product, ST266, is the secretome produced by the AMP cells. It is a completely cell-free solution and is comprised of hundreds of biologically active molecules, including cytokines and growth factors. Interestingly, these cytokines and growth factors exist at very low physiological levels ranging from pg/mL ng/mL concentrations.1 The fact that such low concentrations of these molecules are biologically active is quite remarkable when you consider that traditional protein-based therapies are usually administered at concentrations that are orders of magnitude greater than the concentrations found in ST266.Because the composition of ST266 is so complex, its multiple mechanisms of action have only been partially elucidated. Clinical and preclinical studies have shown ST266 to be anti-inflammatory,2,3 promote wound healing,4,5 reduce apoptosis, reduce vascular permeability (manuscript in preparation), and restore cellular homeostasis.3 Preclinical studies have also shown ST266 to be neuroprotective. In a traumatic brain injury model, ST266 significantly protected against reactive gliosis, suggesting potent anti-inflammatory activity, and resulted in significant recovery of rotarod motor function.6,7 In another study, ST266 was tested in the experimental autoimmune encephalopathy (EAE) mouse model of multiple sclerosis (MS). In this model, the mice develop optic neuritis, which is among the presenting symptoms of MS in humans. ST266 was administered to the nares of mice 15 or 22 days after disease induction. ST266 is absorbed via capillary action along the olfactory nerves which bypasses the blood-brain barrier. This unique route of administration allows for the delivery of high molecular weight biologics to the optic nerve of the eye and the central nervous system. ST266 attenuated visual dysfunction, prevented retinal ganglion cell (RGC) loss, reduced inflammation, and decreased the rate of demyelination of the optic nerve in EAE mice.3Mechanistically, ST266 simultaneously acts on multiple cell receptor-activated and intracellular signaling pathways. For example, in the EAE MS model, neuroprotective effects involved oxidative stress reduction, SIRT1-mediated mitochondrial function promotion, and pAKT signaling.3 In a Phase 2 UV light burn study, ST266 reduced erythema and DNA damage and increased the expression of XPA DNA repair proteins.2Importantly, ST266 has a proven clinical safety profile. It has been administered to 243 patients by various routes of administration (topical skin, topical ocular, topical oral, targeted intranasal), and no drug-related serious adverse events have been reported. Preclinical studies of systemically administered ST266 have also yielded no drug-related safety concerns.LL: For what indications is ST266 currently being evaluated as a treatment?WJG: We refer to ST266 as a platform biologic. By this, we mean that ST266 is one product that has the potential to treat numerous and varied diseases. In the clinic, we have shown anti-inflammatory activity when ST266 is applied topically to UV light-burned the skin2 and topical application to the gums of patients with gingivitis and periodontitis showed a reduction in proinflammatory cytokines in the patients crevicular fluid (manuscript in preparation). We are currently conducting a Phase 2 open label trial of ST266 to treat persistent corneal epithelial defects (PEDs) when applied topically to the eye. Results from this trial will be published soon. We are currently planning a Phase 2b multi-center, randomized, double-masked trial to further evaluate the safety and efficacy of ST266 in this indication. Finally, we are conducting a Phase 1 study in patients at risk for developing glaucoma. This study is using the intranasal route of delivery described above in combination with a novel delivery device. The goal is to deliver ST266 directly to the optic nerve, where it can protect the RGCs that are damaged in glaucoma. We envision this route of delivery will be applicable to central nervous system and other back-of-the eye indications.We also have several ongoing preclinical programs that are evaluating systemically administered ST266 for more generalized inflammatory conditions. These data are not yet published but combined with the data we have compiled in preclinical and clinical studies of topical skin, topical oral and topical ocular administration, we believe ST266 has the potential to be an effective therapy for numerous systemic inflammatory conditions.LL: Could you elaborate on the underlying basis for your evaluation of ST266 as a potential treatment for COVID-19?WJG: As you know, a major complication of COVID-19 is the severe inflammatory response seen in the lungs of some patients. This response is called cytokine storm or cytokine release syndrome. As the pandemic continues and more data have become available, it is now known that the cytokine storm does not just affect the lungs. Multi-organ damage occurs in many of these patients. We believe that systemic delivery of ST266 and its anti-inflammatory activity has the potential to calm the storm. Our as-yet-unpublished preclinical studies with intravenous ST266 support this hypothesis and we are moving rapidly to initiate intravenous ST266 in a Phase 1 study. Once safety in humans is established by this route of administration, we will commence Phase 2 studies in COVID-19 patients.William J. Golden was speaking to Laura Elizabeth Lansdowne, Senior Science Writer for Technology Networks.References

1. Steed, DL, C Trumpower, D Duffy, C Smith, V Marshall, R Rupp, and M Robson. (2008). Amnion-Derived Cellular Cytokine Solution: A Physiological Combination of Cytokines for Wound Healing. Eplasty 8: 15765.

2. Guan, Linna, Amanda Suggs, Emily Galan, Minh Lam, and Elma D. Baron. (2017). Topical Application of ST266 Reduces UV-Induced Skin Damage. Clinical, Cosmetic and Investigational Dermatology. DOI: https://doi.org/10.2147/CCID.S147112.

3. Khan, Reas S, Kimberly Dine, Bailey Bauman, Michael Lorentsen, Lisa Lin, Helayna Brown, Leah R Hanson, et al. (2017). Intranasal Delivery of A Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function In A Mouse Multiple Sclerosis Model. Scientific Reports. DOI: https://doi.org/10.1038/srep41768.

4. Bergmann, Juri, Florian Hackl, Taro Koyama, Pejman Aflaki, Charlotte a Smith, Martin C Robson, and Elof Eriksson. (2009). The Effect of Amnion-Derived Cellular Cytokine Solution on the Epithelialization of Partial-Thickness Donor Site Wounds in Normal and Streptozotocin-Induced Diabetic Swine. Eplasty 9: e49.

5. Franz, Michael G, Wyatt G Payne, Liyu Xing, D K Naidu, R E Salas, Vivienne S Marshall, C J Trumpower, Charlotte A Smith, David L Steed, and M C Robson. (2008). The Use of Amnion-Derived Cellular Cytokine Solution to Improve Healing in Acute and Chronic Wound Models. Eplasty 8: e21.

6. Deng-Bryant, Ying, Zhiyong Chen, Christopher van der Merwe, Zhilin Liao, Jitendra R Dave, Randall Rupp, Deborah a Shear, and Frank C Tortella. (2012). Long-Term Administration of Amnion-Derived Cellular Cytokine Suspension Promotes Functional Recovery in a Model of Penetrating Ballistic-like Brain Injury. The Journal of Trauma and Acute Care Surgery DOI: https://doi.org/10.1097/TA.0b013e3182625f5f.

7. Deng-Bryant, Ying, Ryan D. Readnower, Lai Yee Leung, Tracy L. Cunningham, Deborah A. Shear, and Frank C. Tortella. (2015). Treatment with Amnion-Derived Cellular Cytokine Solution (ACCS) Induces Persistent Motor Improvement and Ameliorates Neuroinflammation in a Rat Model of Penetrating Ballistic-like Brain Injury. Restorative Neurology and Neuroscience. DOI: https://doi.org/10.3233/RNN-140455.

Read the rest here:
Exploring the Therapeutic Potential of ST266 Against Numerous Diseases Including COVID-19 - Technology Networks

Recommendation and review posted by Bethany Smith

The light, non-greasy, dermatologically tested formula contains Vitamin B3 to help hydrate and support the skin barrier, and SPF30 for added sun protection. It alsosits beautifully under your regular SPF you'll have on, and makeup.

It won't clog your pores and doesn't include common irritants like fragrance or colour. The no-fuss formula also won't mess with the rest of your skincare, making it the easy to slot into your existing routine. Done!

(*Side note:Always read the label. Follow the directions for use. Avoid prolonged sun exposure and wear protective clothing, hats and eyewear to further reduce risk. Frequent re-application is required.)

Anyone else get dry lips in winter? This lip balm is brilliant for a few reasons.

A) It's super affordable and accessible - you'll find it at most pharmacies.

B) It has SPF50+ broad spectrum protection.

C) The texture isn't too thick or too thin, it's just right.

And D) You can wear the clear formula over the top of alip stain or lip liner.

Just don't leave it in the car, OK?

(And yes, you know the drill:Always read the label. Follow the directions for use. Avoid prolonged sun exposure and wear protective clothing, hats and eyewear to further reduce risk. Frequent re-application is required.)

View post:
'I found these 4 affordable winter skin saviours in the chemist beauty aisles.' - Mamamia

Recommendation and review posted by Bethany Smith

Oncology is a branch of study and treatment of cancer. Cancer is disease in which abnormal cells grow and divide without control. Oncology drugs help in diagnosis cancer. Some of the causes of cancer are tobacco and smoking, viral infections, genetic causes, carcinogens, bacterial infections, physical activities, eating habits and age. Various types of cancer that can be treated by oncology drugs are blood cancer, endocrine cancer, lung cancer, bone cancer, skin cancer, genitourinary cancer, gastrointestinal cancer, breast cancer, eye cancer, head and neck cancers and gynaecologic cancer. On the basis of treatment, oncology drugs market can be segmented into chemotherapy, immunotherapy, surgery, radiation therapy, stem cell transplant, hormone therapy and others.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/3312

North America, followed by Europe, has the largest market for oncology drugs due to new drug development, government initiatives and developed healthcare infrastructure in this region. Asia is expected to show high growth rate in the oncology drugs market in next few years due to increasing incidence of cancer cases, rise in the use of tobacco products and growth in aging population in the region.

Technological advancement, increasing incidence of various type of cancers, rise in need for R&D activities in cancer and growing concerns over high death rates due to cancer are driving the market for oncology drugs. In addition, introduction of new drugs and therapies for cancer and government support to improve healthcare condition are expected to drive the market for oncology drugs. However, high cost of cancer treatments, strict government regulations, huge investment involvement in the development and clinical trials of the therapies and side effects of cancer treatments are some of the major factors restraining the growth for global oncology drugs market.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/3312

Growing demographics and economies in the developing countries such as China and India are expected to offer good opportunities in oncology drugs market in Asia. In addition, new innovations in cancer drugs and therapies and rise in awareness about the new drugs and therapies available in the market are expected to offer new opportunities for global oncology drugs market. Personalized medicines, increasing number of mergers and acquisitions, new product launches and rise in number of collaborations and partnerships are some of the trends that have been observed in global oncology drugs market.

Some of the major companies operating in the global oncology drugs market are Amgen, Bayer Healthcare AG, CELGENE CORPORATION, GlaxoSmithKline, ARIAD Pharmaceuticals, Inc., Eli Lilly and Company, Novartis, Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim GmbH, Pfizer and Teva Pharmaceuticals Industries.

See the original post:
Rapid Unit Sales of Oncology Drugs to Account for Incremental Revenues in the Global Market - Medic Insider

Recommendation and review posted by Bethany Smith

The modern baking and snack consumer wants packaging that keeps products fresh and tasty as long as possible and offers easy-to-eat, single-serve portions for their on-the-go lifestyle. These consumer demands are driving packaging designers to look toward flexible packaging options.

Flexible packaging now accounts for close to 40% of global packages, according to the Flexible Packaging Assessment Report from PMMI Business Intelligence, part of PMMI. Within flexible packaging, food remains the largest industry by end-use, with biscuits/snack bars and sweet and savory snacks combining to represent the largest growth segment among areas exceeding industry growth rates. This aligns with consumers increasing awareness of the health benefits of snacks such as nuts, dried fruits and nutritional bars.

Per PMMIs report, snack food packaging designs that require smaller pouches for nuts and dried fruit, nutrition bars and even mix-in protein powders facilitate the healthy eating trend and stand to support growth through 2022. CPG companies recognize that food, in general, is experiencing a higher increase in production and sales using flexible packaging, and is moving many in the snack food sector to embrace this format. The industry is now gearing toward on-the-go packaging, user convenience, smaller pack sizes and easy-to-open features. One example cited in the study notes a baking syrup manufacturing company transitioning its products from a can with a pump to a pouch with a dispenser, stating the pouch version is more cost-efficient and easier to make.

While flexible packaging is more sustainable and uses less energy to make, these desirable qualities for CPGs and consumers become a design challenge when looking at end-of-life recycling. There is currently a lack of recycling options for multi-material laminated films, such as snack bags and foil pouches, which are difficult to separate into their various material substrates.

Although many packaging material companies worldwide are scrambling to develop sustainable packaging materials to reduce environmental impact, it is a time-consuming and expensive process. CPGs need to build flexibility into their supply chain as obtaining environmentally friendly materials is not as easy as acquiring more traditional packaging materials. The industry is responding to these supply chain challenges with new initiatives to improve the sustainability profile of flexible packaging. These actions include developing new technologies, such as flexible packaging sortation to drive recycling and collection and auto-sortation of flexible materials. Several manufacturers are continuing to identify techniques to make the collection and sortation of flexible packaging waste feasible and economically friendly. Others continue to investigate new materials for flexible packaging, including compostable or bio-based structures.

According to the report, baked foods are increasing the use of bags and pouches because of the lower cost, shelf-life extension and product visibility. Adding modified atmosphere packaging (MAP) can extend shelf life even more, especially when baked foods include fruits and vegetables as ingredients. Coupling the advances of MAP and high-performance films give CPGs products with excellent mechanical strength and chemical resistance against bacteria growth.

As the industry continues to navigate through the challenges posed by the coronavirus (COVID-19) and the resulting impact onflexible packaging manufacturers, suppliers can visitPMMI's COVID-19 resource pagefor helpful insights on ways to adapt and evolve in a new normal. For further support in overcoming operational challenges and uncovering helpful solutions, Pack Expo International and Healthcare Packaging Expo, set for November 2020,will serve as North America's resource for packaging technologies across a wide range of industries.

See the original post:
The importance of flexible packaging in the snack category - Baking Business

Recommendation and review posted by Bethany Smith

Researchstore.biz has delivered an analysis look at Global Lingonberry Extract Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 collectively with exchange methods, development charge, evolving know-how, business enterprise rivals, key businesses and forecast to 2025. The report studies the data of revenue, production, and manufacturers of each region. Region-wise revenue and volume for the forecast period have also been analyzed. The report offers a close approach towards important developments which is probably expected to have a giant and effect on the progress of the change in the forecast duration from 2020 to 2025. Then, the research report on the global Lingonberry Extract market highlights insightful data about revenue, growth rates, sales, market share for timeframe between 2020 to 2025, and price trends.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/38740

Competitive Landscape:

The competitive landscape analysis as well as market growth trends are explained in detail. Competition matrix benchmarks main players based on their capabilities and boom potential. An in-depth analysis of revenue share, market size, price and gross margin for each industry vendor is offered in this research report. Factors inclusive of market position, offerings, and focus on R&D contribute to an organizations abilities. According to the report, top-line boom, marketplace share, segment boom, and future outlook contribute to an organizations boom potential. This segment additionally identifies and includes numerous latest traits witnessed by using leading players operating in the international Lingonberry Extract market.

Key companies profiled in this report are: Shanghai Freemen , Dongling Health Food , Swanson , Natrol , Bio Botanica , Source Naturals , Athelas Nutraceuticals , Life Extension

With respect to the product bifurcation, the market is segregated into: Powder, Granular

With respect to the application segment bifurcation, the market is segregated into: Food Industry, Pharmaceuticals Industry, Other

Moreover, the report presents an investigation of the global Lingonberry Extract market chain structure, downstream buyers, market positioning, upstream raw material data. The analysis has mentioned the volume of production by region, pricing analysis according to each type, manufacturer, region, and the global price has been given further.

Regional Outlook:

As part of the geographic evaluation of the international Lingonberry Extract industry, this research digs deep into the boom of key regions and countries, consisting of North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). All of the geographies are comprehensively studied on the premise of share, intake, manufacturing, future growth potential, CAGR, and plenty of other parameters.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-lingonberry-extract-market-38740

There Are 12 Chapters To Deeply Display The Lingonberry Extract Market.

Chapter 1, it determines global Lingonberry Extract market introduction, research objectives, and market research methodology

Chapter 2, is an executive summary of Market, exposes assessment of types, and shows an assessment of applications

Chapter 3, Market analysis by players, competition landscape analysis with market size, share, and the concentration ratio

Chapter 4, to reveal the evaluation of regions and courtiers (or sub-regions)

Chapter 5, North America market size by countries, by type, by application

Chapter 6, Europe market size by countries, by type, by application

Chapter 7, Asia-Pacific market size by countries, by type, by application

Chapter 8, South America market size by countries, by type, by application

Chapter 9, Middle East and Africa market size by countries, by type, by application

Chapter 10, to forecast the market in the subsequent years by type, by application

Chapter 11, key players analysis with company details, the product offered, revenue, gross margin and market share

Chapter 12, Research findings and conclusion

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

Click Here For Similar Reports:

Global Touch Screen Tea Table Market 2020 Key Players, Comprehensive Research, SWOT Analysis and Forecast by 2025

Global Class Card Machine Market 2020 Key Players, Comprehensive Research, SWOT Analysis and Forecast by 2025

Global Oxfendazole Market 2020 Key Players, Comprehensive Research, SWOT Analysis and Forecast by 2025

Global Toldimphos Sodium Market 2020 Key Players, Comprehensive Research, SWOT Analysis and Forecast by 2025

Go here to read the rest:
Global Lingonberry Extract Market 2020 In-depth Analysis, Significant Trends and Forecast With COVID-19 Update - 3rd Watch News

Recommendation and review posted by Bethany Smith